Recombinant Human Tumor necrosis factor receptor superfamily member 13B (TNFRSF13B)

中文名稱：

Recombinant Human Tumor necrosis factor receptor superfamily member 13B (TNFRSF13B)
品名簡(jiǎn)稱：

Recombinant Human TNFRSF13B protein, partial
貨號(hào)：

CSB-MP023971HU
說(shuō)明書(shū)：

MSDS Datasheet
規(guī)格：

￥708
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 95% as determined by SDS-PAGE.
生物活性：

Not Test
基因名：

TNFRSF13B
Uniprot No.：

O14836
別名：

Transmembrane activator and CAML interactor;CD antigen CD267
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Partial of Isoform 2
來(lái)源：

Mammalian cell
分子量：

14.7 kDa
表達(dá)區(qū)域：

2-120aa
氨基酸序列

SGLGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCMSCKTICNHQSQRTCAAFCRSLSCRKEQGKFYDHLLRDCISCASICGQHPKQCAYFCENKLRSPVNLPPELRR
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

C-terminal 10xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
基因功能參考文獻(xiàn)：
1. Expression patterns of BAFF and its receptor TACI differ according to lupus nephritis class. PMID: 29087261
2. p.G76S gain-of-function mutation on the TNFRSF13B gene is responsible for familial or sporadic immune thrombocytopenia. PMID: 28834165
3. BAFF-induced processing of BAFFR regulates BAFF-mediated B cell responses in a TACI-dependent manner. PMID: 28249164
4. results suggest that TACI A181E heterozygosity results in TACI haploinsufficiency with increased susceptibility to pneumococcal infection PMID: 27609654
5. genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder PMID: 26623716
6. 11% of common variable immunodeficiency patients and 13% of antibody deficiency syndromes patients carried at least one mutated TNFRSF13B allele. PMID: 27123465
7. serum levels not associated with disease activity in MPO-ANCA-associated renal vasculitis PMID: 25567522
8. In this review, we aim at giving an insight into the genetics underlying the CVID and particularly at outlining the role of TACI and its relative contribution to the development of CVID-like phenotypes in human. PMID: 26096648
9. C104R mutation was associated with common variable immunodeficiency and IgG subclass deficiency. PMID: 26727773
10. TNFRSF13B hemizygosity does not recapitulate autoimmune features of common variable immune deficiency -associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development. PMID: 26100089
11. Common variable immune deficiency patients with heterozygous mutations in TACI alleles increase susceptibility to autoimmune diseases. PMID: 25866827
12. The study demonstrated that there is a remarkable interindividual variability of TACI expression in chronic lymphocytic leukemia, although the majority of patients display low to undetectable TACI. PMID: 25950010
13. Variants of TNFRSF13B were associated with common variable immunodeficiency. PMID: 26122175
14. only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC's capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC's BM dependency PMID: 25723853
15. Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
16. Although the transcriptional controls for alternative splicing of TACI isoforms remain unknown, differential signals via isoforms may control plasma-cell generation. PMID: 25631768
17. In conclusion, we confirmed the prognostic significance of soluble BLyS levels with regard to TFT in CLL patients, and, more importantly, we showed for the first time that sTACI is a powerful prognostic marker, related to parameters of disease activity PMID: 25162001
18. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation. PMID: 25505277
19. genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
20. TNFRSF13B/TACI defects alone do not result in CVID but may be also found frequently in distinct clinical phenotypes, including benign lymphoproliferation and IgG subclass deficiencies. PMID: 23956760
21. TACI mutations enables autoimmune complications in common variable immune deficiency . PMID: 24051380
22. Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations. PMID: 23237420
23. A significant association of TNFRSF13B gene mutations was observed in common variable immunodeficiency patients. PMID: 22884984
24. Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. PMID: 23225259
25. Segregation analysis of a kindred shows that inheriting single or double copy of the Cys104Arg mutation does not necessarily consign an individual to common variable immunodeficiency (CVID). PMID: 22983507
26. Two pediatric Italian male siblings were affected with hypogammaglobulinemia and recurrent respiratory and gastrointestinal infections in association with a novel compound heterozygous I87N/C104R TACI mutation. PMID: 22627058
27. Three SNPs located in TNFRSF13B on 17p11.2 or nearby were significantly associated with IgG level. PMID: 22673310
28. Data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood. PMID: 22697072
29. the identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain PMID: 22076597
30. We conclude that mutations in TACI are the contributing factors for asthma symptoms in Swedish children, although the mechanisms still remain elusive. PMID: 21850030
31. Our data provide further evidence that TNFRSF13B/TACI alterations are not causative of common variable immunodeficiency PMID: 21547394
32. Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. PMID: 21741080
33. primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
34. We have examined the function of TACI coding variants that have been described in patients with common variable immunodeficiency PMID: 21419480
35. In patients with Smith-Magenis syndrome with only 1 TACI allele, we found decreased B-cell expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA. PMID: 21514638
36. mutations result in impaired B cell response through haploinsufficiency PMID: 20889194
37. TACI expression on CD19+ B cells was up-regulated in patients with lupus nephritis PMID: 20974656
38. MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification PMID: 20676093
39. the TNFRSF13B A181E mutation is associated with a very heterogeneous clinical presentation along with variability in B-cell numbers and amount of TACI protein on memory B cells in Common Variable ImmunoDeficiency PMID: 20156508
40. novel mutations identified in this study support the notion of a crucial role for TACI in B cell differentiation PMID: 19629655
41. Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
42. TACI(hi) myeloma cells displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACI(lo) group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment PMID: 15827134
43. 4 of 19 unrelated individuals with common variable immunodeficiency and 1 of 16 individuals with IgA deficiency had a missense mutation in one allele of TNFRSF13B PMID: 16007086
44. identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency PMID: 16007087
45. Review. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. PMID: 16919470
46. The TACI inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
47. simultaneous binding of TACI and HSPG on B cells with APRIL is crucial for IgA production PMID: 17119122
48. TACI-specific signaling inhibits both B cell activating factor of the TNF family receptor (BAFF-R) and CD40-enhanced antibody production from peripheral blood B cells in vitro, although TACI-specific signaling directly induces mild B cell apoptosis. PMID: 17154264
49. This review defines the exact contribution of TACI receptor stimulation by specific triggers in vitro, enabling us to better understand the complex, context-dependent responses initiated by TACI in vivo. PMID: 17171762
50. Role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. PMID: 17392797
顯示更多

收起更多
相關(guān)疾病：

Immunodeficiency, common variable, 2 (CVID2); Immunoglobulin A deficiency 2 (IGAD2)
亞細(xì)胞定位：

Membrane; Single-pass type III membrane protein.
組織特異性：

Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 18153

OMIM: 240500

KEGG: hsa:23495

STRING: 9606.ENSP00000261652

UniGene: Hs.158341